PD-L1 IHC profiling and implications on immunotherapy for breast cancer management: 7th Genomics Tumor Board Meeting

September 6, 2019

Lucence held the 7th National Genomics Tumor Board (GTB) meeting on 6 Sep 2019, at Mount Elizabeth Hospital for physicians from the public and private hospitals.

Our guest speaker, Dr. Tira Tan from Division of Medical Oncology, National Cancer Centre Singapore, presented on “Multiplexed PD-L1 Immunohistochemical Profiling of Breast Cancer and Associated Immunotherapy Implications.”  She elaborated on the use of a new technology called multiplexed PD-L1 IHC to profile breast cancer patients that can lead to the right immune treatments.

The GTB is a regular educational forum organized by Lucence and supported by the Singapore Society of Oncology. It provides a platform for oncologists, pathologists, and geneticists to learn and share about genomic medicine. This GTB was sponsored by AstraZeneca.

For information on the upcoming meetings in 2019, kindly send us your details through this contact form.

Need Help?